Chemomab Therapeutics Ltd. 与精准医疗领域的开拓者Scipher Medicine宣布达成合并协议。此次合作旨在加速其候选药物Nebokitug的开发进程，该药物将进入一项由人工智能技术支持的二期临床试验，以评估其对类风湿关节炎的治疗效果。这一战略举措旨在整合双方在生物技术与数据分析方面的专长，共同推进精准医疗在自身免疫性疾病领域的应用。
Chemomab Therapeutics Ltd. 与精准医疗领域的开拓者Scipher Medicine宣布达成合并协议。此次合作旨在加速其候选药物Nebokitug的开发进程，该药物将进入一项由人工智能技术支持的二期临床试验，以评估其对类风湿关节炎的治疗效果。这一战略举措旨在整合双方在生物技术与数据分析方面的专长，共同推进精准医疗在自身免疫性疾病领域的应用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.